Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 1, 2025

Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA

View original at globenewswire.com
Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The small molecules segment is likely to capture the maximum share (~75%) due to the extensive therapeutic potential of small molecules and the rising occurrence of chronic illnesses

    80% confidence
  • More than 70 companies are offering buffer manufacturing services for different packaging formats; close to 55% of the buffer manufacturing service providers are based in North America

    80% confidence
  • 86% of the buffer manufacturing systems are fabricated using stainless steel; 95% of the buffer systems work automatically with various controls for pH, conductivity, temperature and pressure

    80% confidence
  • Close to 20% of the total partnership deals have been signed in the last two years, showing growing stakeholder interest in buffer manufacturing

    80% confidence
  • The cell and gene therapies segment will grow at a significantly higher CAGR (19.5%) throughout the forecast period

    80% confidence
  • The antibodies segment is likely to capture the maximum share (~55%) of the overall market

    80% confidence
  • The bottles segment captures the majority share (~40%) in the overall market in the current year and is likely to dominate the market in the future

    80% confidence
  • The buffer preparation market size is currently valued at USD 8.58 billion and is projected to reach 17.96 billion by 2035, growing at a CAGR of 7.8% during the forecast period

    80% confidence
  • Over 60% of the firms engaged in this domain manufacture custom buffers; most of these buffers have been formulated as liquid bottles

    80% confidence
  • The market in Asia-Pacific is likely to grow at a high CAGR (8%), during the forecast period

    80% confidence
  • The liquid formulations segment is likely to capture the maximum share (~70%) due to liquid buffers providing consistency between batches and minimizing the chance of human mistakes

    80% confidence
  • Around 60 buffer manufacturing systems are currently available in the market for stabilizing drug components in biopharmaceuticals; notably, most of these buffer systems are offered by players based in the US

    80% confidence
  • North America is likely to capture the majority share (~40%) in the overall market currently, and this trend is unlikely to change in the future

    80% confidence
  • The reusable buffer mixing / preparation equipment market segment is likely to capture the majority share (~80%) in the overall market in the current year and is likely to grow at a relatively faster rate during the forecast period

    80% confidence
  • The commercial scale segment is likely to capture the maximum share (~85%) and this trend is likely to remain the same in the coming years

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com